Legal & General Group
TEVA icon

Legal & General Group’s Teva Pharmaceuticals TEVA Stock Holding History

Legal & General Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133M Buy
3,916,666
+43,855
+1% +$1.46M 0.03% 454
2026
Q1 		$117M Buy
3,872,811
+264,424
+7% +$8.51M 0.03% 474
2025
Q4 		$113M Buy
3,608,387
+228,189
+7% +$5.62M 0.03% 497
2025
Q3 		$68.3M Buy
3,380,198
+231,457
+7% +$4.07M 0.02% 578
2025
Q2 		$52.8M Buy
3,148,741
+158,401
+5% +$2.56M 0.01% 607
2025
Q1 		$46M Sell
2,990,340
-259,922
-8% -$4.64M 0.01% 631
2024
Q4 		$71.6M Sell
3,250,262
-142,893
-4% -$2.6M 0.02% 561
2024
Q3 		$61.1M Buy
3,393,155
+98,277
+3% +$1.72M 0.02% 598
2024
Q2 		$53.5M Sell
3,294,878
-277,651
-8% -$4.28M 0.02% 608
2024
Q1 		$50.4M Sell
3,572,529
-92,222
-3% -$1.16M 0.01% 634
2023
Q4 		$38.3M Buy
3,664,751
+164,227
+5% +$1.53M 0.01% 676
2023
Q3 		$35.7M Buy
3,500,524
+4,133
+0.1% +$38.5K 0.01% 683
2023
Q2 		$26.3M Buy
3,496,391
+138,117
+4% +$1.12M 0.01% 767
2023
Q1 		$29.7M Sell
3,358,274
-6,325,524
-65% -$62.5M 0.01% 719
2022
Q4 		$88.3M Buy
9,683,798
+1,534,941
+19% +$13.4M 0.03% 489
2022
Q3 		$65.8M Buy
8,148,857
+126,299
+2% +$1.12M 0.03% 565
2022
Q2 		$60.3M Sell
8,022,558
-219,828
-3% -$1.92M 0.02% 599
2022
Q1 		$77.4M Buy
8,242,386
+316,017
+4% +$2.64M 0.02% 588
2021
Q4 		$63.5M Sell
7,926,369
-847,309
-10% -$7.65M 0.02% 639
2021
Q3 		$85.5M Buy
8,773,678
+45,016
+0.5% +$422K 0.03% 570
2021
Q2 		$86.4M Buy
8,728,662
+3,980,002
+84% +$42.1M 0.03% 572
2021
Q1 		$54.8M Buy
4,748,660
+2,456,578
+107% +$28.2M 0.02% 645
2020
Q4 		$22.1M Sell
2,292,082
-621
-0% -$5.95K 0.01% 823
2020
Q3 		$20.7M Sell
2,292,703
-262,187
-10% -$2.77M 0.01% 780
2020
Q2 		$31.5M Buy
2,554,890
+81,673
+3% +$924K 0.02% 683
2020
Q1 		$22.2M Buy
2,473,217
+53,893
+2% +$552K 0.01% 706
2019
Q4 		$23.7M Buy
2,419,324
+144,933
+6% +$1.29M 0.01% 766
2019
Q3 		$15.6M Buy
2,274,391
+164,071
+8% +$1.26M 0.01% 844
2019
Q2 		$19.5M Buy
2,110,320
+272,515
+15% +$3.29M 0.01% 802
2019
Q1 		$28.8M Buy
1,837,805
+1,129,595
+160% +$19.9M 0.02% 663
2018
Q4 		$10.9M Buy
708,210
+117,894
+20% +$2.42M 0.01% 811
2018
Q3 		$12.7M Sell
590,316
-372
-0.1% -$8.64K 0.01% 813
2018
Q2 		$14.4M Sell
590,688
-21,231
-3% -$433K 0.01% 785
2018
Q1 		$10.5M Buy
611,919
+77,766
+15% +$1.52M 0.01% 812
2017
Q4 		$10.1M Buy
534,153
+16,542
+3% +$249K 0.01% 806
2017
Q3 		$9.11M Buy
517,611
+650
+0.1% +$14.6K 0.01% 794
2017
Q2 		$17.2M Sell
516,961
-73,141
-12% -$2.26M 0.01% 685
2017
Q1 		$18.9M Buy
590,102
+32,515
+6% +$1.11M 0.02% 659
2016
Q4 		$20.2M Buy
557,587
+537,276
+2,645% +$21.5M 0.02% 634
2016
Q3 		$935K Sell
20,311
-8,555
-30% -$446K ﹤0.01% 1425
2016
Q2 		$1.45M Sell
28,866
-2,351
-8% -$125K ﹤0.01% 1065
2016
Q1 		$1.67M Sell
31,217
-10,110
-24% -$593K ﹤0.01% 954
2015
Q4 		$2.71M Buy
41,327
+243
+0.6% +$15K ﹤0.01% 863
2015
Q3 		$2.32M Buy
41,084
+10,666
+35% +$692K ﹤0.01% 879
2015
Q2 		$1.8M Buy
30,418
+8,600
+39% +$531K ﹤0.01% 986
2015
Q1 		$1.36M Sell
21,818
-11,747
-35% -$683K ﹤0.01% 1030
2014
Q4 		$1.93M Sell
33,565
-13,479
-29% -$751K ﹤0.01% 896
2014
Q3 		$2.53M Sell
47,044
-18,217
-28% -$965K ﹤0.01% 822
2014
Q2 		$3.42M Sell
65,261
-3,518
-5% -$180K ﹤0.01% 776
2014
Q1 		$3.63M Buy
68,779
+20,600
+43% +$952K ﹤0.01% 748
2013
Q4 		$1.93M Sell
48,179
-30,432
-39% -$1.2M ﹤0.01% 825
2013
Q3 		$2.97M Sell
78,611
-11,534
-13% -$450K ﹤0.01% 756
2013
Q2 		$3.53M Buy
+90,145
New +$3.51M ﹤0.01% 714

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Legal & General Group's TEVA Position: Q2 2026 in Review

Legal & General Group increased its Teva Pharmaceuticals (TEVA) stake by 1.1% in Q2 2026, buying an estimated $1.46M and bringing the position to 3,916,666 shares worth $133M. The position accounts for 0.03% of the portfolio, ranked #454.

Legal & General Group first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Legal & General Group held 3,916,666 shares of Teva Pharmaceuticals worth $133M as of Q2 2026.
  • Legal & General Group bought 43,855 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.46M.
  • Teva Pharmaceuticals made up 0.03% of Legal & General Group's portfolio in Q2 2026, its #454 holding.
  • Legal & General Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.